{"doi":"10.1126/sciadv.adn9961","title":"Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity","abstract":"<jats:p>\n            mRNA neoantigen cancer vaccine inducing neoantigen-specific T cell responses holds great promise for cancer immunotherapy; however, its clinical translation remains challenging because of suboptimal neoantigen prediction accuracy and low delivery efficiency, which compromise the in vivo therapeutic efficacy. We present a lipopolyplex (LPP)–formulated mRNA cancer vaccine encoding tandem neoantigens as a cancer therapeutic regimen. The LPP-formulated mRNA vaccines elicited robust neoantigen-specific CD8\n            <jats:sup>+</jats:sup>\n            T cell responses in three syngeneic murine tumor models (CT26, MC38, and B16F10) to suppress tumor growth. Prophylactic cancer vaccine treatment completely prevented tumor development, and long-lasting memory T cells protected mice from tumor cell rechallenge. Combining the vaccine with immune checkpoint inhibitor further boosted the antitumor activity. Of note, LPP-based personalized cancer vaccine was administered in two cancer patients and induced meaningful neoantigen-specific T cell and clinical responses. In conclusion, we demonstrated that the LPP-based mRNA vaccine can elicit strong antitumor immune responses, and the results support further clinical evaluation of the therapeutic mRNA cancer vaccine.\n          </jats:p>","journal":"Science Advances","year":2024,"id":634725,"datarank":0.611630616585858,"base_score":4.07753744390572,"endowment":4.07753744390572,"self_citation_contribution":0.611630616585858,"citation_network_contribution":0.0,"self_endowment_contribution":0.611630616585858,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":58,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":513877,"name":"Congcong Xu","orcid":"0000-0003-0710-3750","position":1,"is_corresponding":false},{"id":274028,"name":"Jichuan Wu","orcid":"0000-0003-0068-5049","position":2,"is_corresponding":false},{"id":903127,"name":"Yihua Cai","orcid":"0000-0002-7331-1200","position":3,"is_corresponding":false},{"id":1646359,"name":"Wanlu Cao","orcid":"0000-0002-6298-2623","position":4,"is_corresponding":false},{"id":57874,"name":"Haifa Shen","orcid":"0000-0002-9728-5430","position":5,"is_corresponding":false},{"id":1646363,"name":"Mingna Zhang","orcid":null,"position":6,"is_corresponding":false},{"id":1624566,"name":"Hanfei Zhu","orcid":null,"position":7,"is_corresponding":false},{"id":1574409,"name":"Jingxian Yang","orcid":null,"position":8,"is_corresponding":false},{"id":1607447,"name":"Zhounan Zhu","orcid":null,"position":9,"is_corresponding":false},{"id":106565,"name":"Xiaopin Ma","orcid":null,"position":10,"is_corresponding":false},{"id":1646368,"name":"Jiale Ren","orcid":null,"position":11,"is_corresponding":false},{"id":286449,"name":"Lei Huang","orcid":"0000-0003-4236-1448","position":12,"is_corresponding":false},{"id":1106622,"name":"Qianyun Li","orcid":"0000-0001-5089-2084","position":13,"is_corresponding":false},{"id":1646371,"name":"Yuying Tang","orcid":null,"position":14,"is_corresponding":false},{"id":238229,"name":"Bo Yu","orcid":"0000-0003-4836-9985","position":15,"is_corresponding":false},{"id":1646372,"name":"Chunxiu Chen","orcid":"0009-0007-4433-2241","position":16,"is_corresponding":false},{"id":1646373,"name":"Mingcheng Xu","orcid":null,"position":17,"is_corresponding":false},{"id":1646374,"name":"Qiuhe Wang","orcid":null,"position":18,"is_corresponding":false},{"id":1646375,"name":"Zhuya Xu","orcid":null,"position":19,"is_corresponding":false},{"id":1646376,"name":"Fengjia Chen","orcid":"0009-0004-4283-9936","position":20,"is_corresponding":false},{"id":1646378,"name":"Shujing Liang","orcid":null,"position":21,"is_corresponding":false},{"id":1646379,"name":"Zhixian Zhong","orcid":null,"position":22,"is_corresponding":false},{"id":630324,"name":"Anmbreen Jamroze","orcid":"0009-0006-0444-820X","position":23,"is_corresponding":false},{"id":263780,"name":"Dean G. Tang","orcid":"0000-0001-5029-1174","position":24,"is_corresponding":false},{"id":1646380,"name":"Hangwen Li","orcid":"0009-0007-8852-4501","position":25,"is_corresponding":false},{"id":1574414,"name":"Chunyan Dong","orcid":"0000-0003-2392-3185","position":26,"is_corresponding":false},{"id":1423974,"name":"Ting Fan","orcid":"0000-0002-4021-149X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity","abstract":"<jats:p>\n            mRNA neoantigen cancer vaccine inducing neoantigen-specific T cell responses holds great promise for cancer immunotherapy; however, its clinical translation remains challenging because of suboptimal neoantigen prediction accuracy and low delivery efficiency, which compromise the in vivo therapeutic efficacy. We present a lipopolyplex (LPP)–formulated mRNA cancer vaccine encoding tandem neoantigens as a cancer therapeutic regimen. The LPP-formulated mRNA vaccines elicited robust neoantigen-specific CD8\n            <jats:sup>+</jats:sup>\n            T cell responses in three syngeneic murine tumor models (CT26, MC38, and B16F10) to suppress tumor growth. Prophylactic cancer vaccine treatment completely prevented tumor development, and long-lasting memory T cells protected mice from tumor cell rechallenge. Combining the vaccine with immune checkpoint inhibitor further boosted the antitumor activity. Of note, LPP-based personalized cancer vaccine was administered in two cancer patients and induced meaningful neoantigen-specific T cell and clinical responses. In conclusion, we demonstrated that the LPP-based mRNA vaccine can elicit strong antitumor immune responses, and the results support further clinical evaluation of the therapeutic mRNA cancer vaccine.\n          </jats:p>","is_dataset_classified":null,"base_score":4.02535169073515,"endowment":4.02535169073515,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39392882","pmcid":"PMC11468906","openalex_id":"https://openalex.org/W4403329686","authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"P30 CA016056","title":null}],"total_grants":1,"fwci":8.4079,"citation_percentile":0.98499949,"influential_citations":0,"citation_trend":[{"year":2023,"count":1},{"year":2024,"count":2},{"year":2025,"count":30},{"year":2026,"count":22}],"oa_status":"gold","license":"cc-by-nc","oa_locations":[{"url":"https://www.science.org/doi/pdf/10.1126/sciadv.adn9961?download=true","host_type":"journal"},{"url":"https://www.science.org/doi/pdf/10.1126/sciadv.adn9961?download=true","host_type":"publisher"},{"url":"https://www.science.org/doi/pdf/10.1126/sciadv.adn9961","host_type":"publisher"},{"url":"https://doi.org/10.1126/sciadv.adn9961","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39392882","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11468906","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC11468906","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC11468906?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Immunotherapy and Immune Responses","RNA Interference and Gene Delivery","Monoclonal and Polyclonal Antibodies Research","Cancer Vaccines","Animals","Antigens, Neoplasm","Mice","Humans","Cell Line, Tumor","CD8-Positive T-Lymphocytes","RNA, Messenger","Female","mRNA Vaccines","Neoplasms","Immunotherapy","T-Lymphocytes","Disease Models, Animal","Mice, Inbred C57BL"],"mesh_terms":["mRNA Vaccines","Animals","Antigens, Neoplasm","Disease Models, Animal","Female","Humans","Immunotherapy","Mice, Inbred C57BL","Neoplasms","RNA, Messenger","T-Lymphocytes","CD8-Positive T-Lymphocytes","Cancer Vaccines","Cell Line, Tumor","Mice"],"keywords":["Cancer immunotherapy","Cancer vaccine","Immune system","Medicine","Cancer","Immunotherapy","T cell","CD8","Cancer research","Immunology","Internal medicine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T14:05:10.972876Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}